elacridar has been researched along with Leukemia, Myeloid, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, JF; Boer, R; Buchholz, F; Gekeler, V; Niethammer, D; Sanders, KH; Ulrich, WR | 1 |
| Elgie, AW; Lewandowicz, GM; Sargent, JM; Taylor, CG; Williamson, CJ | 1 |
2 other study(ies) available for elacridar and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative.
Topics: Acridines; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blood Proteins; Calcium Channel Blockers; CD56 Antigen; Cyclosporins; Dihydropyridines; Dose-Response Relationship, Drug; Flow Cytometry; Fluorescent Dyes; Gene Expression; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Morpholines; Multidrug Resistance-Associated Proteins; Pyrimidines; Rhodamine 123; Rhodamines; Tetrahydroisoquinolines; Verapamil | 1998 |
Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML.
Topics: Acridines; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Bone Marrow; Cell Survival; Cyclosporine; Daunorubicin; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Tetrahydroisoquinolines; Tumor Cells, Cultured | 1999 |